Skip to main content

Table 1 Serological HPV 6,11,16,18 and 45 genotype-specific outcomes* as related to Any-HPV detection in the genital samples at the follow-up visits

From: Outcomes of HPV type-specific serostatus do not associate with oral or genital HPV-carriage in non-vaccinated women followed for three years

  

Baseline

2 months

12 months

24 months

36 months

HPV type

Serological outcome

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

HPV + n (%)

HPV − n (%)

 

Always Seronegative

10 (24.4)

58 (31.0)

15 (38.5)

53 (28.3)

26 (23.2)

41 (36.3)

40 (32.3)

26 (30.6)

33 (29.2)

30 (34.1)

HPV 6

Seroconversion

2 (4.9)

3 (1.6)

0 (0.0)

5 (2.7)

3 (2.7)

2 (1.8)

4 (3.2)

0 (0.0)

2 (1.8)

1 (1.1)

 

Persistent Seropositivity

29 (70.7)

126 (67.4)

24 (58.5)

129 (69.0)

83 (74.1)

70 (61.9)

80 (64.5)

59 (69.4)

78 (69.0)

57 (64.8)

 

Always Seronegative

27 (77.1)

160 (85.1)

28 (87.5)

157 (80.1)

80 (80.0)

103 (81.7)

100 (84.7)

78 (83.0)

98 (84.5)

75 (83.3)

HPV11

Seroconversion

0 (0.0)

4 (2.1)

0 (0.0)

4 (2.0)

0 (0.0)

4 (3.2)

1 (0.8)

0 (0.0)

1 (0.9)

1 (1.1)

 

Persistent Seropositivity

8 (22.8)

31 (15.9)

4 (12.5)

35 (17.9)

20 (20.0)

19 (15.1)

17 (14.4)

16 (17.0)

17 (14.7)

14 (15.6)

 

Always Seronegative

15 (44.1)

134 (69.4)

20 (66.7)

128 (65.6)

61 (57.5)

84 (71.8)

76 (63.9)

65 (73.0)

74 (65.5)

63 (70.8)

HPV16

Seroconversion

0 (0.0)

12 (6.2)

0 (0.0)

11 (5.6)

7 (6.6)

5 (4.3)

6 (5.0)

3 (3.4)

8 (7.1)

2 (2.2)

 

Persistent Seropositivity

19 (55.9)

47 (24.4)

10 (33.3)

56 (28.7)

38 (35.8)

28 (23.9)

37 (31.1)

21 (23.6)

31 (27.4)

24 (27.0)

 

Always Seronegative

26 (63.4)

164 (77.7)

27 (69.2)

162 (76.8)

85 (74.6)

101 (75.4)

101 (76.5)

77 (76.2)

100 (79.4)

72 (72.0)

HPV18

Seroconversion

2 (4.9)

9 (4.3)

2 (5.1)

9 (4.3)

5 (4.4)

6 (4.5)

8 (6.1)

3 (3.0)

4 (3.2)

7 (7.0)

 

Persistent Seropositivity

13 (31.7)

38 (18.0)

10 (25.6)

40 (19.0)

24 (21.1)

27 (20.1)

23 (17.4)

21 (20.8)

22 (17.4)

21 (21.0)

 

Always Seronegative

37 (90.2)

206 (91.2)

34 (89.5)

207 (91.2)

112 (88.2)

127 (93.4)

133 (89.9)

95 (95.0)

127 (92.0)

94 (92.2)

HPV45

Seroconversion

0 (0.0)

4 (1.8)

0 (0.0)

4 (1.8)

3 (2.4)

1 (0.7)

1 (0.7)

2 (2.0)

2 (1.4)

1 (1.0)

 

Persistent Seropositivity

4 (9.8)

16 (7.1)

4 (10.5)

16 (7.0)

12 (9.4)

8 (5.9)

14 (9.5)

3 (3.0)

9 (6.5)

7 (6.9)

  1. *Serological status was categorized into three groups as followed: 1) Always seronegative, MFI value < 200 at each visit; 2) Seroconversion, defined by two conditions: (i) an MFI value < 200 in the first and > 200 in any subsequent sample, and (ii) at least a two-fold increase of the previous serum value; and 3) Persistent seropositivity, with MFI value > 200 in all follow-up samples. Significant results are bolded
Back to article page

BMC Women's Health

ISSN: 1472-6874

Contact us